FreudenreichOGoffDC. Antipsychotic combination in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand2002;106:323–30.
2.
KapurSZipurskyRBRemingtonGJonesCDaSilvaJWilsonAA, and others. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. Am J Psychiatry1998;155:921–8.
3.
YokoiFGrunderGBiziereKStephaneMDoganASDannalsRF, and others. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): A study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology2002;27:248–59.
4.
MooreHWestARGraceAA. The regulation of forebrain dopamine transmission: Relevance to the pathophysiology and psychopathology of schizophrenia. Biol Psychiatry1999;46:40–55.
5.
MillanMJGobertANewman-TancrediALejueneFCussacDRivetJM, and others. S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-receptors: I. Receptor, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther2000; 293:1048–62.
6.
MeltzerHY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology1999;21(suppl 2):106S–15S.
7.
KaneJMCarsonWHSahaARMcQuadeRDIngenitoGZimbroffDL, and others. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry2002;63:763–71.
8.
WetzelHHillertAGrunderGBenkertO.Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms. Am J Psychiatry1994; 151:1499–2.
9.
BurrisKDMolskiTFXuCRyanETottoriKKikuchiT, and others. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther2002;302:381–9.
